Duloxetine + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anxiety Neuroses
Conditions
Anxiety Neuroses, Anxiety States, Neurotic, Neuroses, Anxiety
Trial Timeline
Jun 1, 2011 → Jun 1, 2013
NCT ID
NCT01226511About Duloxetine + Placebo
Duloxetine + Placebo is a phase 3 stage product being developed by Eli Lilly for Anxiety Neuroses. The current trial status is completed. This product is registered under clinical trial identifier NCT01226511. Target conditions include Anxiety Neuroses, Anxiety States, Neurotic, Neuroses, Anxiety.
What happened to similar drugs?
19 of 20 similar drugs in Anxiety Neuroses were approved
Approved (19) Terminated (2) Active (1)
✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01931475 | Phase 3 | Completed |
| NCT01451606 | Approved | Terminated |
| NCT01226511 | Phase 3 | Completed |
| NCT01179672 | Phase 3 | Completed |
| NCT01237587 | Phase 3 | Completed |
| NCT01118780 | Approved | Completed |
| NCT01070329 | Approved | Completed |
| NCT01000805 | Approved | Completed |
| NCT01018680 | Phase 3 | Completed |
| NCT00965081 | Approved | Completed |
| NCT00803361 | Phase 3 | Completed |
| NCT00767806 | Phase 3 | Completed |
| NCT00433290 | Phase 3 | Completed |
| NCT00424593 | Phase 3 | Completed |
| NCT00457730 | Phase 2/3 | Completed |
| NCT00408876 | Phase 3 | Completed |
| NCT00408421 | Phase 3 | Completed |
| NCT00607789 | Approved | Completed |
| NCT00375973 | Phase 2/3 | Completed |
| NCT00233025 | Phase 3 | Completed |
Competing Products
20 competing products in Anxiety Neuroses